Table 1.
Baseline and perioperative characteristics compared between the matched early steroid withdrawal and continued steroid groups
| Variable | Continued Steroid, n=5565 | Early Steroid Withdrawal, n=5565 |
|---|---|---|
| Median transplant year (IQR) | 2007 (2004–2008) | 2006 (2005–2008) |
| Mean recipient age, yr ±SD | 49.5±12.6 | 49.8±12.7 |
| Women, % | 38.6 | 38.7 |
| Recipient BMI, kg/m2 ±SD | 28.3±5.5 | 28.3±5.7 |
| Primary insurance Medicare/Medicaid, % | 73.8 | 73.2 |
| History of diabetes, % | 33.4 | 34.1 |
| Preemptive transplant, % | 9.3 | 10.0 |
| Retransplant, % | 6.9 | 7.0 |
| Mean donor age, yr ±SD | 39.3±15.7 | 39.4±15.7 |
| Living donor, % | 17.2 | 17.4 |
| Donor ECD, % | 16.1 | 16.3 |
| Donor DCD, % | 8.9 | 9.1 |
| Black donor, % | 31.9 | 31.9 |
| Woman donor, % | 42.3 | 42.6 |
| Median waiting time, yr (IQR) | 1.8 (0.7–3.3) | 1.7 (0.7–3.3) |
| Median HLA mismatches (IQR) | 5 (3–5) | 4 (3–5) |
| Median current PRA, % (IQR) | 0 (0–7) | 0 (0–7) |
| Median peak PRA, % (IQR) | 2 (0–19) | 2 (0–18) |
| Median cold ischemic time, h (IQR) | 16.8 (9.4–23.3) | 16.0 (8.0–23.5) |
| Immunosuppression, % | ||
| IL-2 RA induction therapy | 14.6 | 12.8 |
| Cytolytic induction therapy | 67.4 | 68.1 |
| Tacrolimus | 83.1 | 82.6 |
| Cyclosporin | 9.1 | 7.8 |
| MMF/MPA | 83.5 | 81.5 |
| Azathioprine | 0.9 | 0.5 |
| mTOR inhibitor | 11.5 | 11.2 |
| Delayed graft function, % | 23.4 | 22.6 |
| Propensity score | 0.29±0.15 | 0.31±0.15 |
IQR, interquartile range; BMI, body mass index; ECD, expanded criteria donor; DCD, donor after circulatory death; PRA, panel reactive antibody; RA, receptor antibody; MMF, mycophenolate mofetil; MPA, mycophenolic acid; mTOR, mammalian target of rapamycin.